Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
Linda Blake, PharmD, PhD, BCPS, Alison Palumbo, PharmD, MPH, BCOP, Amber Diaz, PharmD, BCOP, Joseph Bubalo, PharmD, BCPS, BCOP
A paradigm shift in the management of relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma (NHL) has evolved in recent years. With increased use of targeted therapies, ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, is an integral therapeutic option for patients with treatment-naïve and treatment-experienced CLL or low-grade NHL. Ibrutinib therapy demonstrated superior overall response rates compared with ofatumumab and other agents in treatment-experienced patients with CLL.
Results 1 - 6 of 6